Yeda Research and Develpment & Co. Ltd

Immunobrain Checkpoint, Inc.

Neuroquest Inc.

Ester Yoles

Michal Eisenbach-Schwartz

Kuti Baruch

Jan Egebjerg

Jonathan Kipnis

Oleg Butovsky

Ehud Hauben

Carol David

Allan Jensen

Berit Olsen Krogh

Ravid Shechter

Omer Miller

Inbal Benhar Bar-On

The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease

A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3cells, CD19cells, CD56cells and optionally CD16cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.

Human monocyte sub-population for treatment of eye diseases and disorders

Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

Vaccine and method for treatment of neurodegenerative diseases

A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3cells, CD19cells, CD56cells and optionally of CD16cells, for use in treatment of CNS injury is provided.

Human monocyte sub-population for treatment of central nervous system injury

Methods and compositions are provided for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), or for protecting nerves from glutamate toxicity, which comprises administering to an individual in need thereof an effective amount of the copolymer poly-Glu,Tyr.

Poly-Glu,Tyr for neuroprotective therapy

Methods and compositions are provided for preventing or inhibiting neuronal degeneration, or for promoting nerve regeneration, in the central nervous system (CNS) or peripheral nervous system (PNS), or for protecting CNS cells from glutamate toxicity, comprising an effective amount of an agent selected from the group consisting of (a) poly-Glu,Tyr and (b) T cells which have been activated by poly-Glue,Tyr.

Growing community of inventors

Moshav Beit Gamliel, Israel

Ester Yoles